ArticleRadiology. Imaging cancer2024
External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans.
Abstract readValidation Study
In one paragraph
Article in Radiology. Imaging cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- Apparent diffusion coefficient radiomics for differentiating benign and malignant PI-RADS 3-5 prostate lesions: external validation.International urology and nephrology · 2026Article
- Autonomous AI in prostate cancer: the road ahead towards clinical implementation.Abdominal radiology (New York) · 2026Review
- Deep learning for clinically significant prostate cancer detection on MRI: a systematic review, HSROC meta-analysis, and direct comparison with PI-RADS-based interpretation.Abdominal radiology (New York) · 2026Article
- PI-RADS v2.1 for prostate MRI: current applications, ongoing debates, and synergies with advanced technologies-a narrative review.Translational andrology and urology · 2026Review
- Clinical and MRI features for predicting maximum cancer involvement of >50% in a single biopsy core among patients diagnosed with prostate cancer at initial systematic biopsy: a machine learning study.American journal of cancer research · 2026Article
- Research-based clinical deployment of artificial intelligence algorithm for prostate MRI.Abdominal radiology (New York) · 2025Article
- Impact of AI-Generated ADC Maps on Computer-Aided Diagnosis of Prostate Cancer: A Feasibility Study.Academic radiology · 2025Article
- Review
- Novel Voxel-Based MRI Risk Score LADCTCancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Enis C YilmazFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0001-5301-3137
Stephanie A HarmonFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-2507-2399
Yan Mee LawFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-6499-4281
Erich P HuangFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Mason J BelueFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-1298-9958
Yue LinFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0003-4143-174X
David G GelikmanFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-4317-2561
Kutsev B OzyorukFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Dong YangFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-5031-4337
Ziyue XuFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-5728-6869
Jesse TetreaultFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0009-0001-3057-8626
Daguang XuFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Lindsey A HazenFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0003-4013-8226
Charisse GarciaFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Nathan S LayFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-3548-9251
Philip EclarinalFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-3115-7495
Antoun ToubajiFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0009-0000-3841-2359
Maria J MerinoFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Bradford J WoodFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-4297-0051
Sandeep GurramFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).
Peter L ChoykeFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0003-1086-8826
Peter A PintoFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0002-0190-5931
Baris TurkbeyFrom the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).ORCID 0000-0003-0853-6494
Funding
NCI NIH HHS NCT00102544NCI NIH HHS NCT02594202NCI NIH HHS NCT03354416
Abstract
Purpose To evaluate the performance of an artificial intelligence (AI) model in detecting overall and clinically significant prostate cancer (csPCa)-positive lesions on paired external and in-house biparametric MRI (bpMRI) scans and assess performance differences between each dataset. Materials and Methods This single-center retrospective study included patients who underwent prostate MRI at an external institution and were rescanned at the authors' institution between May 2015 and May 2022. A genitourinary radiologist performed prospective readouts on in-house MRI scans following the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 or 2.1 and retrospective image quality assessments for all scans. A subgroup of patients underwent an MRI/US fusion-guided biopsy. A bpMRI-based lesion detection AI model previously developed using a completely separate dataset was tested on both MRI datasets. Detection rates were compared between external and in-house datasets with use of the paired comparison permutation tests. Factors associated with AI detection performance were assessed using multivariable generalized mixed-effects models, incorporating features selected through forward stepwise regression based on the Akaike information criterion. Results The study included 201 male patients (median age, 66 years [IQR, 62-70 years]; prostate-specific antigen density, 0.14 ng/mL
Indexed as
Deep LearningMagnetic Resonance ImagingProstatic NeoplasmsAgedAlgorithmsHumansImage-Guided BiopsyImage Interpretation, Computer-AssistedMaleMiddle AgedProstateRetrospective StudiesMR ImagingProstateUrinary
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.